AstraZeneca PLC
ZEG
Company Profile
Business description
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
Contact
1 Francis Crick Avenue
Cambridge Biomedical Campus
CambridgeCB2 0AA
GBRT: +44 2037495000
E: ir@astrazeneca.com
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
94,300
Stocks News & Analysis
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 7,561.70 | 142.70 | -1.85% |
| CAC 40 | 6,903.01 | 197.41 | -2.78% |
| DAX 40 | 19,800.25 | 480.01 | -2.37% |
| Dow JONES (US) | 37,806.25 | 160.66 | 0.43% |
| FTSE 100 | 7,711.85 | 198.68 | -2.51% |
| HKSE | 20,264.49 | 136.81 | 0.68% |
| NASDAQ | 15,512.36 | 244.45 | 1.60% |
| Nikkei 225 | 31,714.03 | 1,298.55 | -3.93% |
| NZX 50 Index | 11,806.55 | 84.89 | -0.71% |
| S&P 500 | 5,021.59 | 38.82 | 0.78% |
| S&P/ASX 200 | 7,375.00 | 135.00 | -1.80% |
| SSE Composite Index | 3,186.81 | 41.26 | 1.31% |